CDK1 and ovarian cancer: Additional cell cycle regulators were also altered, including up-regulated CDK6, which has been previously described based on its aberrant expression and association with paclitaxel-based therapy in ovarian cancer patients [30, 31] and also including CDK7, which regulates the assembly of the CDK1/Cyclin B1 complex [32, 33].